I
INEX INNOVATE PTE., LTD.
INEX Innovate is Asia's first molecular diagnostics company for women. To date, the group has launched 5 diagnostics tests, 7 different laboratory workflows, and developed a broad range of IP. Emerging from the National University of Singapore (NUS), INEX is based in Singapore and was founded by veteran maternal fetal medicine specialists. Backed by institutional investors, it is uniquely positioned to identify and address clinically unmet needs within women's and fetal health landscape. The company focuses on developing and translating technologies that aim to deliver precision healthcare for women in Asia. INEX Innovate develops diagnostics to support clinical decisions for various unmet women's health conditions, including in the oncology and reproductive health space. It has received significant interest from gynaecologists and onco-gynaecologists both in Singapore and the broader Southeast Asian markets, reinforcing the view that demand exists for unique solutions with clinical appeal and companies like INEX to step up to the challenge of catering to this emerging market. Through their wholly owned subsidiary iGene Laboratory, INEX operates a state of the art Next Generation Sequencing Laboratory that provides diagnostic testing, clinical research (CRO) and COVID-19 testing services. In 2021, INEX received the Frost & Sullivan 'Singapore Clinical Laboratories in Women's Health Entrepreneurial Company of the Year Award' and was also recognised by World Intellectual Property Organization (WIPO) and the Intellectual Property Office of Singapore (IPOS) with the 2021 IP for Innovation Champion Award. In 2022, the company was named one of Singapore's Fastest Growing Companies 2022 by The Straits Times and ranked as 7th Fastest Growing Health Care companies across Asia-Pacific by the Financial Times.
Country/Area ：Singapore
Company Email ：contact@inex.sg
Industry ：Medical Testing & Clinical LaboratoriesHealthcare
Company address ：1 Science Park Road #04-10 the Capricorn, Singapore, Central Singapore, 117528, Singapore
Company website ：*****
Company phone ：+65 67730698
Established ：2006
Company Revenue ：$4,057,000
Number of employees ：<25
SIC Code ：80807
NAICS Code ：62621
Main Products ：Investor RelationsOvaCis®XENA®epiDx®PartnershipsLaboratoryLEXI®AnnouncementsepiHERA™
Company News
Molecular Diagnostics Developer INEX Innovate Announces Funding for New Research with The Chinese University of Hong Kong
Jul 26, 2022
Singapore-based diagnostics developer INEX Innovate brings The Chinese University of Hong Kong together to further research work on LEXI®, INEX's fetal cell based non-invasive pre-natal diagnostics technology. SINGAPORE, July 26, 2022 /PRNewswire/ -- Singapore-based diagnostics developer and medical laboratory operator, INEX Innovate has contributed an undisclosed sum to leading Hong Kong university – The Chinese University of Hong Kong (CUHK), to collaborate and further research in the field of
Jul 26, 2022
iGene Laboratory launches Monkeypox PCR test for the South East Asian region.Jul 8, 2022
SINGAPORE, July 8, 2022 /PRNewswire/ -- iGene Laboratory, the molecular diagnostics laboratory subsidiary of INEX Innovate Pte Ltd, announces the launch of its research-use-only (RUO) polymerase chain reaction (PCR) Monkeypox test in response to the recent outbreak of the virus. The iGene Laboratory team The Monkeypox virus predominately occurs in Central and Western Africa, that causes a disease with symptoms similar to Smallpox – fever, headache, swollen lymph nodes, fatigue, and muscle aches
Jul 8, 2022Asia's first molecular diagnostics company for women, INEX Innovate receives European CE-IVD Certification for its OvaCis(R) Rapid Test to detect cancer in ovarian cysts.May 11, 2022
Revolutionary Ovarian Cancer Rapid Test Available Q4 2022 SINGAPORE, May 11, 2022 /PRNewswire/ -- Known as a pioneer in Asia's women's and fetal health industry, Singapore-based diagnostics developer, INEX Innovate has obtained a CE mark for its lead ovarian cancer product, the OvaCis®...
May 11, 2022Singapore-based women's healthcare company marks its first Financial Times rankingApr 11, 2022
Making its debut on the fourth annual Financial Times ranking of 500 of Asia-Pacific's high-growth companies, INEX Innovate - the pioneering healthcare technology company targeting women's health - is one of only 20 healthcare companies listed in the prestigious line up. SINGAPORE, April 11, 2022 /PRNewswire/ -- Emerging from the National University of Singapore (NUS), INEX Innovate is a Singapore-based molecular diagnostics developer and medical laboratory operator. The company was founded by a
Apr 11, 2022iGene Laboratory donates 25,000 SARS-CoV-2 PCR Kits to IndonesiaSep 15, 2021
iGene Laboratory Pte. Ltd donates 25,000 SARS-CoV-2 PCR Kits to Indonesia to assist the government of the Republic of Indonesia in managing the COVID-19 disease outbreak. The occasion was marked with a symbolic hand-over ceremony at the Republic of Indonesia Embassy in Singapore on 13 September 2021 hosted by the Indonesian Ambassador, H.E. Suryo Pratomo.
Sep 15, 2021Web Summary
Q1: What is the company name and its location?
A1: The company name is INEX Innovate Pte. Ltd., and it is located at Head Office: 1 Science Park Road #04-10, The Capricorn, Singapore 117528, and Laboratory: 1 Science Park Road #04-10, The Capricorn, Singapore 117528.
Q2: What products does the company develop and commercialize?
A2: INEX Innovate develops and commercializes new technologies to address unmet needs in women's and fetal health. Some of its notable products include OvaCis, epiDx, epiHERA, XENA, and LEXI.
Q3: What is the company's focus on?
A3: The company's focus is on improving women's health through innovative diagnostics. It aims to deliver precision healthcare solutions to address unmet needs in women's and fetal health.
Q4: What is epiHERA, and how does it work?
A4: epiHERA is a Minimally Invasive Early Endometrial Cancer Detection Test that uses real-time PCR analyses to detect cancer. The test involves taking a simple sample collection using the common HPV swab, extracting DNA, undergoing bisulfite conversion, and then screening through real-time PCR analyses.
Q5: What is OvaCis, and how does it work?
A5: OvaCis accurately discriminates benign from malignant epithelial ovarian cysts in 15 minutes. It uses a similar process as epiHERA, involving DNA extraction, bisulfite conversion, and real-time PCR analyses.
Q6: What is the company's commitment to innovation?
A6: INEX Innovate is dedicated to applying its R&D and proven commercial capabilities to address unmet needs in women's and fetal health. The company continuously seeks collaborators to support existing research and clinical programs, diversify its portfolio with new technology, and accelerate the development of innovative diagnostics tools.
Q7: What are some of the company's partnerships?
A7: INEX Innovate partners with various organizations to support its mission. These include collaborations with researchers, clinicians, and other companies to develop innovative diagnostics solutions for women's health challenges.
Q8: How can one contact INEX Innovate?
A8: One can contact INEX Innovate through its head office at +65 6773 0698 or by sending an email to [info@inexinnovate.com](mailto:info@inexinnovate.com). The company also has a laboratory located at the same address.
A1: The company name is INEX Innovate Pte. Ltd., and it is located at Head Office: 1 Science Park Road #04-10, The Capricorn, Singapore 117528, and Laboratory: 1 Science Park Road #04-10, The Capricorn, Singapore 117528.
Q2: What products does the company develop and commercialize?
A2: INEX Innovate develops and commercializes new technologies to address unmet needs in women's and fetal health. Some of its notable products include OvaCis, epiDx, epiHERA, XENA, and LEXI.
Q3: What is the company's focus on?
A3: The company's focus is on improving women's health through innovative diagnostics. It aims to deliver precision healthcare solutions to address unmet needs in women's and fetal health.
Q4: What is epiHERA, and how does it work?
A4: epiHERA is a Minimally Invasive Early Endometrial Cancer Detection Test that uses real-time PCR analyses to detect cancer. The test involves taking a simple sample collection using the common HPV swab, extracting DNA, undergoing bisulfite conversion, and then screening through real-time PCR analyses.
Q5: What is OvaCis, and how does it work?
A5: OvaCis accurately discriminates benign from malignant epithelial ovarian cysts in 15 minutes. It uses a similar process as epiHERA, involving DNA extraction, bisulfite conversion, and real-time PCR analyses.
Q6: What is the company's commitment to innovation?
A6: INEX Innovate is dedicated to applying its R&D and proven commercial capabilities to address unmet needs in women's and fetal health. The company continuously seeks collaborators to support existing research and clinical programs, diversify its portfolio with new technology, and accelerate the development of innovative diagnostics tools.
Q7: What are some of the company's partnerships?
A7: INEX Innovate partners with various organizations to support its mission. These include collaborations with researchers, clinicians, and other companies to develop innovative diagnostics solutions for women's health challenges.
Q8: How can one contact INEX Innovate?
A8: One can contact INEX Innovate through its head office at +65 6773 0698 or by sending an email to [info@inexinnovate.com](mailto:info@inexinnovate.com). The company also has a laboratory located at the same address.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
